FDA Fast-Tracks Gene-Silencing Drug for Devastating Childhood Epilepsy

BOSTON, MA – June 22, 2026 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to elsunersen, an investigational drug developed by Praxis Precision Medicines, offering a new ray of hope for children with a rare and severe form of genetic epilepsy. The designation, announced today, is for the treatment of seizures associated with SCN2A Developmental and Epileptic Encephalopathy (SCN2A-DEE) caused by specific genetic variants and is intended to expedite the development and review of a therapy that could become the first to treat the underlying cause of the disease.

This regulatory milestone is based on striking results from a clinical trial that showed a dramatic reduction in seizures and broader developmental improvements in young patients. For families navigating the challenges of SCN2A-DEE, a condition marked by relentless seizures starting in infancy and profound developmental delays, the news signals a potential paradigm shift from managing symptoms to directly targeting the genetic root of the disorder.

“Our third Breakthrough Therapy Designation for the late-stage pipeline is a defining milestone for Praxis, with immediate implications for the elsunersen program and for our Solidus™ ASO platform,” said Marcio Souza, president and chief executive officer of Praxis. “It reflects the FDA’s recognition of both the urgency of the unmet need in SCN2A-DEE and the strength of our clinical data... this designation allows us to move with greater clarity and speed to bring elsunersen to patients and families as quickly as possible.”

A Precision Strike Against a Genetic Storm

SCN2A-DEE is a catastrophic neurological disorder caused by mutations in the SCN2A gene. This gene provides instructions for making the NaV1.2 sodium channel, a critical component of nerve cells that helps control the brain's electrical signaling. In patients with so-called Gain-of-Function (GoF) variants, the mutated gene leads to overactive sodium channels, creating a “genetic storm” of excessive electrical activity that manifests as difficult-to-control seizures.

Seizures often begin within the first few months of life and are frequently accompanied by severe intellectual disability, movement disorders, and autism spectrum disorder. Currently, there are no approved therapies that address the genetic defect itself. Standard anti-seizure medications are often ineffective and can sometimes paradoxically worsen the condition, leaving a profound unmet medical need.

Elsunersen (also known as PRAX-222) represents a new frontier in treatment. It is an antisense oligonucleotide (ASO), a short strand of synthetic genetic material designed to bind to the messenger RNA produced by the faulty SCN2A gene. This binding action effectively “silences” the gene, reducing the production of the overactive NaV1.2 protein. By turning down the volume on the problematic gene, elsunersen aims to quell the electrical storm at its source, offering the potential to not only control seizures but also modify the course of the disease.

Unpacking the Compelling Clinical Evidence

The FDA’s decision was heavily influenced by positive data from the EMBRAVE Part A trial, a randomized, sham-controlled Phase 1/2 study involving nine pediatric patients aged 2 to 12. The results were not just statistically significant; they were clinically profound.

Patients treated with elsunersen experienced a 77% sham-adjusted reduction in monthly seizures compared to baseline, a highly significant outcome (p=0.015). The impact was consistent and substantial: 71% of children receiving the therapy saw their seizure frequency drop by more than half, and a remarkable 57% experienced at least one continuous 28-day period completely free of seizures during the six-month study. This efficacy was sustained for up to a year in patients who continued into an open-label extension of the trial.

Perhaps most encouraging were the signs of broader, disease-modifying effects. Beyond seizure control, 100% of the children treated with elsunersen showed improvements in other areas, including sleep, motor function, muscle tone, and neuropsychomotor development. In stark contrast, none of the patients in the sham group demonstrated these additional benefits. The therapy was also well-tolerated, with no drug-related serious adverse events or discontinuations reported.

Bolstered by this data and close alignment with the FDA, Praxis is now enrolling patients in the pivotal EMBRAVE3 study. This trial has been streamlined into a single-arm, baseline-controlled design, meaning all approximately 30 participants will receive elsunersen, further accelerating its path toward potential approval.

Validating a Platform, Building a Pipeline

The success of elsunersen is a major strategic victory for Praxis Precision Medicines, a biopharmaceutical company focused on translating genetic insights into new therapies for central nervous system disorders. This marks the company’s third Breakthrough Therapy Designation for a late-stage asset, underscoring the productivity of its research and development engine.

The designation serves as a powerful validation of the company's Solidus™ ASO platform, which underpins elsunersen, and its broader precision neuroscience approach. Praxis’s diversified portfolio includes other promising candidates, such as ulixacaltamide for essential tremor and relutrigine for other genetic epilepsies, both of which have also received BTD and are under review by the FDA. This robust pipeline has attracted significant attention from analysts, who see the company as a leader in the precision CNS space and poised to transition from a clinical-stage to a commercial organization.

The Power of the Breakthrough Pathway

The FDA's Breakthrough Therapy Designation is a critical mechanism designed to accelerate the development of drugs for serious or life-threatening conditions where preliminary evidence suggests a substantial improvement over available therapies. It is more than an honorary title; it is an all-hands-on-deck commitment from the agency.

For a drug like elsunersen, this means more intensive FDA guidance, collaborative meetings with senior agency officials, and eligibility for programs like rolling review, which allows a company to submit sections of its marketing application as they are completed. It also makes the drug eligible for priority review, which shortens the FDA’s review timeline from the standard ten months to six. For rare disease communities like those affected by SCN2A-DEE, where time is of the essence, this accelerated pathway can be transformative, potentially shaving years off the traditional drug development timeline.

As the pivotal EMBRAVE3 study moves forward, the Breakthrough Therapy Designation ensures that elsunersen will remain on the fastest possible track, bringing a potential disease-modifying therapy one step closer to the children who urgently need it.